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Supplementary Appendix 
 
Supplementary Methods: 
 
Genetic studies 
 
Whole exome sequencing of the selected individuals was performed at the Broad 
Institute. Hybrid selection was performed using Agilent’s SureSelect Human All Exon 
Kit v2 (Agilent Technologies, Santa Clara, CA). We sequenced the samples using the 
Illumina HiSeq 2000 platform (Illumina Inc, San Diego, CA) and aligned the resulting 
reads to the human genome version 19 reference genome with Burrows-Wheeler Aligner 
(http://bio-bwa.sourceforge.net/).1 We then applied the Genome Analysis Toolkit 
(http://www.broadinstitute.org/gatk),2 base quality score recalibration, and indel 
realignment, and performed single nucleotide polymorphism and indel discovery and 
genotyping across all samples simultaneously using variant quality score recalibration.3 
Variants were annotated for functional effect using SnpEff 2.0.5 
(http://snpeff.sourceforge.net/).4 
 
For PCR amplification of the MKRN3 the following primers pairs were used: 1F: 5’-
GGGGAAGGAAAAAGAGATGC-3’, 1R: 5’-AGCCATCTGCTTCCTCTCAG-3’; 2F: 
5’-CCAATTGCAACCATTCCTTC-3’, 2R: 5’-CACCATAATCCTAGGGGGAAA-3’. 
Amplification reactions were performed in a final volume of 50 μl containing 20 pmol of 
each primer, 150 ng template DNA, 200 μmol/L dNTPs, 2.5 U Taq polymerase, 2.5 μl 
10x buffer containing 1.5 mM MgCl2 and carried out for 30 cycles: denaturation at 94оC 
for 30 sec, annealing at 59-60оC for 30 sec, extension at 72оC for 1 min, followed by a 
final extension for 10 min at 72оC. All PCR products were separated on 1% agarose gel 
electrophoresis and sequenced at the Dana-Farber/Harvard Cancer Center DNA Resource 
Core (Boston, MA).  
 
Quantitative real-time PCR 
 
One microgram of total RNA was reverse transcribed using the Superscript III cDNA 
synthesis kit (Invitrogen), followed by quantitative real-time PCR analysis of murine 
Mkrn3 on an ABI Prism 7000 sequence detection system (Applied Biosystems, Foster 
City, CA). SYBR green mix (Bio-Rad, Hercules, CA) was used according to the 
manufacturer’s instructions. Levels of mRNA were normalized to ribosomal protein L19 
as an internal control. The following primer pairs were used to amplify Mkrn3: F: 5’-
AAGCGCATACTGGCATCAAG-3’; R: 5’-AGCCAACGGTCATCAGAGAA-3’ and 
L19: F: 5’-CTGAAGGTCAAAGGGAATGTG-3’; R: 5’-
GGACAGAGTCTTGATGATCTC-3’. The results were analyzed using ABI Prism 7000 
SDS software (Applied Biosystems), and data presented as fold change compared to P10. 
 
Supplementary Results: 
 
Genotype-Phenotype Correlation 
 
Family A 
 
The frameshift heterozygous variant in MKRN3, c.637delC, p.Arg213Glyfs*73, was 
identified in the three affected siblings of this family from the United States of European 
ancestry and in the unaffected father (Figure 1). DNA from the paternal grandmother was 
not available for genetic studies but her history of early age of menarche suggests that 
individual II.1, the father of the affected siblings, inherited this variant from his mother 
but does not manifest the CPP phenotype because only the paternally inherited MKRN3 
allele is expressed. The unaffected family members III.4, III.5, and II.2 are wild-type for 
MKRN3. The proband presented with thelarche at age 5 years 9 months and pubic hair 
Tanner stage 2 at 6 years and 6 months (III.1). Her sister also presented with early 
thelarche at age 6 years 6 months (III.3). Her brother had increased testicular volume at 
age 8 (III.2). All siblings had pubertal basal and stimulated luteinizing hormone (LH) 
levels and advanced bone age upon diagnosis of CPP (Table 1). The deletion of cytosine 
637 in the MKRN3 results in a frameshift mutation in the amino acid 213 of the protein 
and in a premature stop codon generating a truncated protein of 286 instead of 507 amino 
acids (Figure 2).  
 
Family B 
 
The heterozygous insertion of an adenosine at position 1171 of MKRN3, 
c.1171_1172insA, p.Tyr391*, was identified in the two affected siblings of a Brazilian 
family (III.1 and III.2) and in their affected father, aunt and grandfather (I.1, II.2 and II.3) 
(Figure 1). The two affected siblings presented with early thelarche at age 6 years and 3 
months (III.1) and 5 years and 9 months (III.2) and pubertal levels of stimulated LH 
(Table 1). The insertion of an adenosine at position 1171 of MKRN3 results in a stop 
codon at this position and generates a protein of 391 amino acids instead of 507, lacking 
the last zinc finger motif (Figure 2). 
 
Family C 
 
A novel missense mutation, c.1095G>T, p.Arg365Ser, was identified in the MKRN3 in 
all three affected siblings from a Caucasian family in Belgium (Figure 1). The proband 
presented with thelarche at age 6 years and 3 months (III.1) and her sister with thelarche 
and pubarche at age 5 years and 5 months (III.3). Upon diagnosis patient III.1 was 6 
years and 5 months and patient III.3 was 5 years and 9 months, both had advanced bone 
age, and pubertal stimulated LH levels (Table 1). The brother presented at 9 years 9 
months with advanced bone age, testicular enlargement and Tanner stage 3 pubic hair 
(III.2). It was not entirely clear at what age puberty began but his first clinical 
presentation suggested the diagnosis of precocious puberty. The mutation was inherited 
from their father (II.1), who carries the mutation but is not affected; their mother (II.2) is 
wild type for MKRN3. Both parents had a history of normal pubertal development. 
Arginine 365 is located in the RING-type zinc finger and is highly conserved among 
species (Figure 2). The p.Arg365Ser substitution is predicted to affect protein function 
with a Polyphen2 score of 1.0 and Panther Pdeleterious of 0.95.  
 
Family D  
 
A heterozygous insertion of a cytosine, c.C475_476insC, p.Ala162Glyfs*14, was 
identified in two siblings with CPP in a Brazilian family (Figure 1). Patient III.2 has a 
history of penile and pubic hair maturation at age 5 years 11 months. He sought medical 
assistance at age 8 years 1 month, presenting with a bone age of 10 years, testicular size 
of 10 ml bilaterally, and penile length of 9.5 cm. His hormonal profile corroborated the 
diagnosis of CPP with pubertal basal and stimulated LH levels and high testosterone 
levels (Table 1). His brother (II.3) also has a history of early penile and pubic hair 
maturation and sought medical assistance at age 9 years and eight months with Tanner 
stage 3 pubic hair and testis. Following the pattern of paternal imprinting, both siblings 
inherited the mutation from their father (II.1), who carries the mutation but is not affected 
and likely inherited the variant from his mother. However we have neither clinical history 
nor DNA from his mother (Figure 1). This insertion results in a truncated protein of 176 
amino acids (Figure 2). 
 
Family E  
 
The two affected siblings from this family from the United States of European ancestry, 
also harbor the variant c.475_476insC, p.Ala162Glyfs*14, identified in family D (Figure 
1). The proband (III.1) had increased testicular volume and penile enlargement at age 8 
years 6 months. His sister had thelarche at age 5 years (III.2). Upon diagnosis the boy 
was 8 years and 10 months and the girl 6 years and 6 months, both had advanced bone 
age and pubertal GnRH stimulated LH levels (Table 1). The unaffected father of Italian 
ancestry also has the variant in the heterozygous state, corroborating the paternal 
imprinting pattern of segregation. The unaffected mother is homozygous wild-type for 
MKRN3 gene. It is possible that families D and E are distantly related. We have not 
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Supplementary Figure S1. 
 Supplementary Figure S1: Pedigrees of families without MKRN3 mutations. Black 
symbols are affected subjects and white symbols are unaffected subjects. Arrows indicate 
the proband in each family. Individuals with asterisks were screened with exome 
sequencing.
Supplementary Table S1. Clinical and hormonal features of patients with familial CPP selected for whole exome sequencing, 
without MKRN3 defects.  
Family Patient 
Number 
 
Initial Clinical 
Presentation 
(Age in Years) 
Diagnosis LH 
IU/L 
FSH 
IU/L 
 E2 
pg/mL 
Additional Cases £ 
(Age in Years) 
   Age 
(Years) 
Breast 
Tanner Stage 
Bone Age 
(Years)  
Basal Post 
GnRH 
Basal Post 
GnRH 
  
F III.1 Thelarche (4.5) 6.4 3 7.8 <0.6 11.4 1.6 12.7 <13 I.2 Menarche (10.0) 
 III.2 Thelarche (5) 8.0 4 11.0 1.7 - 3.9 - 34.6  
 III.5* Thelarche (5.8) 6.7 4 11.0 1.9 31.5 6.2 12.8 53.3  
 III.9 Thelarche and 
pubarche (5.9) 
6.9 4 11.0 1.6 - 4.7 - 29  
G III.7* Thelarche (7.7) 8.2 3 11.0 <0.6 17.6 4.2 - 31 II.5 Menarche (8.0) 
III.6 Menarche (9.0) 
H III.1* Thelarche and 
pubarche (5.0) 
5.5 3 11.0 1.0 8.8 1.9 - 17.4 I.2 Menarche (8.0) 
II.1 Menarche (9.0) 
I III.1* Thelarche (6.5) and 
menarche (10.0) 
10.2 4 11.0 4.2 39.5 2.6 13.7 99 - 
 III.2 Thelarche (6.8) and 
menarche (9.7) 
9.8 4 11.5 2.2 - 4.6 - <13  
J III.1* Thelarche and 
pubarche (7.3) 
8.0 3 11.0 1.5 46 2.7 - <13 - 
 III.2 Thelarche and 
pubarche (7.5) 
7.9 3 12.0 <0.6 6.9 1.2 - 13  
K III.1* Thelarche and 
pubarche (6.6) 
7.3 4 9.5 0.1 16 3.7 - 13 I.2 Menarche (10.0) 
II.1 Menarche (9.0) 
and short stature 
L III.1* Thelarche and 
pubarche (5.5) 
7.2 3 7.8 <0.6 6.5 1.5 20.0 <13 II.1 Menarche (10.0) 
M III.1* Thelarche (3.0) 6.0 4 8.8 <0.6 9.8 3.7 16.1 <13 III.5 Thelarche (3.0) 
N III.1* Thelarche (1.8) 8.0 4 10.0 0.1 6.9 2.2 13.0 <13 II.2 Menarche (9.0) 
 III.2 Thelarche (7.0) 6.4 3 11.5 2.5 6.5 6.9 9.2 25  
O III.1* Thelarche (7.4) 7.8 2 10.0 0.2ϯ 18.6ϯ 1.6 ϯ 11.0 ϯ 24 - 
 III.2 Thelarche (6.9) 7.8 2 11.0 <0.07 ϯ 5.0 ϯ 1.4 ϯ 9.3ϯ 29  
E2: estradiol; T: testosterone 
Normal values: T (FIA): prepubertal levels < 19 ng/dl; E2 (FIA): prepubertal levels < 21 pg/ml; LH (IFMA)5: prepubertal basal levels < 0.6 (IU/L), 
peak < 6.9 (IU/L) in girls and < 9.6 (IU/L) in boys.  ϯ LH (ICMA): prepubertal basal levels < 0.15 (IU/L), peak <5.0 (IU/L) in both girls and boys.  
Normal pubertal levels of FSH have not been established because the normal ranges for pubertal and prepubertal FSH overlap. 
Breast Tanner stage and bone age assessed at time of diagnosis.  *Index case; £ Relatives with clinical history suggestive of precocious puberty. 
   
